EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DNA Methylation and p53 Immunohistochemistry as Prognostic Biomarkers for Vulvar Lichen Sclerosus

Féline O Voss, Johannes Berkhof, Sylvia Duin, Guus Fons, Marc van Beurden, Renske D M Steenbergen, Maaike C G Bleeker

Modern Pathology · 2024

DOI: 10.1016/j.modpat.2024.100553 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2024. Verfasst von Féline O Voss und 6 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC location Vrije Universiteit Amsterdam, Pathology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterda…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, DNA Methylation, Tumor Suppressor Protein p53, Vulvar Lichen Sclerosus. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vulvar lichen sclerosus (LS) is an inflammatory dermatosis that can progress to human papillomavirus (HPV)-independent vulvar intraepithelial neoplasia (HPVi VIN) and vulvar squamous cell carcinoma (VSCC). Although LS has a much lower cancer risk compared with HPVi VIN (5% vs 50%, respectively), its incidence is significantly higher. Therefore, there is a clinical need to identify LS patients with an increased cancer risk. Our objective was to study the value of DNA methylation and p53 immunohistochemistry (IHC) as prognostic biomarkers for progression to cancer in patients with LS. Vulvar tissues from 236 patients were selected, including 75 LS and 68 HPVi VIN, both with and without cancer development, 32 VSCC, and 61 healthy vulvar controls. Samples were subjected to p53 IHC and DNA methylation analysis of a 3-gene marker panel containing ZNF582, SST, and miR124-2. Methylation levels and p53 IHC status (mutant or wild-type) were assessed and compared among all disease categories. Odds ratios were determined to identify whether the biomarkers were associated with progression to cancer in patients with LS. The highest methylation levels were found in HPVi VIN and VSCC, followed by LS and healthy vulvar controls. The largest heterogeneity in methylation levels was observed in LS cases. In fact, the 3-marker panel tested positive in 70% of LS, which progressed to VSCC vs only 17% of LS in patients without cancer development (P = .002). Also, mutant p53 IHC was observed more frequently in LS with progression to VSCC compared with nonprogressive LS cases (42% vs 3%, respectively, P = .001). Multivariable analysis identified a mutant p53 status as the only independent risk factor for cancer development in LS (odds ratio: 34.0, 95% CI: 1.4-807.4). In conclusion, DNA methylation testing and p53 IHC show strong potential as prognostic biomarkers for the identification of LS patients at high risk of progression to cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorDNA MethylationTumor Suppressor Protein p53Vulvar Lichen SclerosusVulvar NeoplasmsAdultAgedAged, 80 and overFemaleHumansMiddle AgedCarcinoma in SituCarcinoma, Squamous CellDisease ProgressionImmunohistochemistryPrognosis

Stichwörter der Autor:innen

DNA methylationbiomarkerlichen sclerosusp53 immunohistochemistryvulvar cancer

Substanzen

Biomarkers, TumorTP53 protein, humanTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Amsterdam UMC location Vrije Universiteit Amsterdam, Pathology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
  • Amsterdam UMC location Vrije Universiteit Amsterdam, Epidemiology and Data Science, Amsterdam, The Netherlands.
  • Amsterdam UMC location Vrije Universiteit Amsterdam, Gynecology, Amsterdam, The Netherlands.
  • Netherlands Cancer Institute/Antoni Van Leeuwenhoek Hospital, Gynecology, Amsterdam, The Netherlands.
  • Amsterdam UMC location Vrije Universiteit Amsterdam, Pathology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands. Electronic address: mcg.bleeker@amsterdamumc.nl.

Zitieren

APA

Voss, F. O., Berkhof, J., Duin, S., Fons, G., van Beurden, M., Steenbergen, R. D. M., & Bleeker, M. C. G. (2024). DNA Methylation and p53 Immunohistochemistry as Prognostic Biomarkers for Vulvar Lichen Sclerosus. Modern Pathology. https://doi.org/10.1016/j.modpat.2024.100553

Vancouver

Voss FO, Berkhof J, Duin S, Fons G, van Beurden M, Steenbergen RDM, et al. DNA Methylation and p53 Immunohistochemistry as Prognostic Biomarkers for Vulvar Lichen Sclerosus. Modern Pathology. 2024. doi:10.1016/j.modpat.2024.100553

BibTeX
@article{Voss2024,
  author = {Voss, Féline O and Berkhof, Johannes and Duin, Sylvia and Fons, Guus and van Beurden, Marc and Steenbergen, Renske D M and Bleeker, Maaike C G},
  title = {DNA Methylation and p53 Immunohistochemistry as Prognostic Biomarkers for Vulvar Lichen Sclerosus},
  journal = {Modern Pathology},
  year = {2024},
  doi = {10.1016/j.modpat.2024.100553}
}
Kostenlos starten →